Article
Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma.
International journal of clinical and experimental pathology - 1 Jan 2015
Li Huanhuan, Wang Yuli, Su Fan, Li Jing, Gong Ping
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor (EGFR) mutation detection has become a routine molecular test with significant implications for prognosis and therapeutic options of EGFR tyrosine kinase inhibitors (EGFR-TKIs). However, acquiring sufficient amounts of tissue for analyzing EGFR mutations is not often feasible, and not all the patients with sensitive EGFR mutations have benefit from EGFR-TKI treatment....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.